Monsanto the disposition of product lines unrelated to agriculture. In 1985, Monsanto acquired G. D. Searle & Company, a life sciences company that focused on pharmaceuticals, agriculture and animal health. In 1993, its Searle division filed a patent application for Celebrex, which in 1998 became the first selective COX‑2 inhibitor to be approved by the U.S. Food and Drug Administration (FDA). Celebrex became a blockbuster drug and was often mentioned as a key reason for Pfizer's acquisition of Monsanto's pharmaceutical business in 2002. In 1994, Monsanto introduced a recombinant version of bovine somatotropin, brand-named Posilac. Monsanto later sold this business to
Monsanto September 2016, Bayer announced its intent to acquire Monsanto for US$66 billion. After gaining US and EU regulatory approval, the sale was completed on June 7, 2018. In 1901 Monsanto was founded in St. Louis, Missouri, as a chemical company. The founder was John Francis Queeny, a 30‑year veteran of the nascent pharmaceutical industry. He funded the firm with his own money and capital from a soft drink distributor. He used his wife's maiden name for the company. The company's first products were commodity food additives, such as the artificial sweetener saccharin, caffeine and vanillin. Monsanto expanded to Europe in